OVERVIEW
DRUG-ELUTING TECHNOLOGY
CLINICAL DATA
ELUVIA
OVERVIEW
DRUG-ELUTING TECHNOLOGY
CLINICAL DATA
ELUVIA
Statistically significant difference in primary patency (p-0.0119) ELUVIA 88.5% vs Zilver PTX 79.5% - Kaplan-Meier Estimate
 
Eluvia demonstrated statistically significant difference in primary patency compared to Zilver™ PTX™ at 12 months in the IMPERIAL Trial.
 
Hear IMPERIAL Principal Investigator, William Gray, MD review the IMPERIAL Trial Results

Hear IMPERIAL Principal Investigator, William Gray, MD review the IMPERIAL Trial Results

Chart comparing paclitaxel release over time for the Eluvia Drug-Eluting Stent, drug-coated balloons and traditional drug-coated stents.

Drug Tissue Concentrations Over Time2

Investing in Drug-Eluting Technology

Find out how we’re leveraging nearly 20 years of design and development experience to advance the science of drug-eluting technologies and improve patient lives.

 
Sign Up Today

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore Resources

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Top